The research group runs Germany's national anti-doping laboratory analysis centre, and their interest in RU58841 is practical: it's an androgen receptor blocker that's freely available online, and if it gets into an athlete's system, it could plausibly interfere with the hormone-level tests used in doping control. That's a different motivation from a dermatology trial, but the underlying question, does this compound get into the body when applied to the scalp, is exactly the one the hair loss community has been debating for years.

Before dosing, the researchers also tested the product itself. It was labelled as 5% RU58841 (50mg/mL). Measured directly, it came out at 30mg/mL, 40% below the label. That's not this study's main finding, but it's a concrete, current data point on how reliably grey-market RU58841 products actually match their stated concentration.

Intact RU58841 was detected in the blood of all six participants after the single application, appearing within hours, peaking within the first 12 hours (the highest individual reading was approximately 5 micrograms per millilitre), and declining toward near-baseline levels by around 36 hours. It remained detectable across the group for up to 168 hours (7 days), with one participant still returning a low but detectable reading after the 120-hour mark. One of its metabolites (M3, formed by oxidation) was also detected in blood within the first 12 hours. In the researchers' own words, the findings indicate RU58841 "is systemically available after topical administration and therefore has the potential of exhibiting systemic effects."

In urine, five separate metabolites were identified, formed through oxidation, N-dealkylation, and glucuronidation of the parent compound. The parent compound declined substantially in blood within roughly 36 hours, but several metabolites remained detectable in urine for much longer, in some cases for nearly nine days (up to 213 hours) after a single application.

This is a small study (six participants), from a single application rather than the repeated daily use people actually practice, but it's a controlled, directly measured result in real humans, and it provides direct human evidence against a specific, previously untested claim: that RU58841 remains entirely local after topical scalp application.

RU58841 belongs to a different drug class from finasteride and dutasteride, and the distinction matters more than it might first appear. Finasteride and dutasteride are 5-alpha-reductase inhibitors: they reduce production of one downstream hormone, DHT, while leaving testosterone largely free to keep signalling through the androgen receptor as normal. RU58841 is a direct, competitive androgen receptor antagonist. Wherever it reaches sufficient concentration in the body, it doesn't reduce a hormone, it blocks the receptor itself from responding to both testosterone and DHT. That's a more direct suppression of androgen signalling in whatever tissue it reaches, not a smaller or gentler version of what 5-alpha-reductase inhibitors do.

This isn't a theoretical distinction. Direct androgen receptor antagonists are an established drug class, prescribed for prostate cancer, and their systemic effects at clinically active exposure are documented in real trial data, not forum anecdotes.

Standard pharmacology references describe direct androgen receptor antagonists as a class carrying documented risk of "emotional and cognitive changes, depression," alongside "cardiovascular disturbances," specifically distinguishing this class from 5-alpha-reductase inhibitors like finasteride and dutasteride. RU58841 itself has been described in earlier pharmacological characterisation as a highly potent antagonist at the receptor, comparable in potency to hydroxyflutamide, an active metabolite from this same drug class.

Worth being precise about the limits of this comparison: the depression, anxiety, and cardiovascular effects documented for bicalutamide and enzalutamide come from studies using full therapeutic doses, in prostate cancer patients, designed specifically to fully suppress androgen signalling as cancer treatment. Nobody has measured whether RU58841's confirmed but comparatively modest systemic exposure from topical scalp use reaches a similar degree of receptor occupancy anywhere else in the body. That uncertainty cuts both ways: it means the comparison isn't a direct one-to-one prediction of what RU58841 does, but it also means nobody can currently rule it out either. What the comparison does establish is that the mechanism itself, systemic androgen receptor blockade, is not a hypothetical or exotic risk. It is the same broad pharmacological mechanism underlying a documented, quantified pattern of neuropsychiatric and cardiovascular effects in its closest approved relatives, and RU58841 is now confirmed to reach systemic circulation, establishing that it is not confined to the scalp.

The study also checked whether the absorbed RU58841 shifted a specific set of urinary hormone ratios (testosterone-to-epitestosterone and related markers) that anti-doping labs monitor to catch athletes disrupting their own androgen production. That's the study's actual reason for existing: the research group runs Germany's national anti-doping analysis centre, and their question was whether RU58841 could confound a drug test, not whether RU58841 is safe to use on a scalp for years.

After the single dose, none of the six participants showed a shift in those markers. Worth being direct about this rather than dressing it up: that result has very limited bearing on the safety questions that actually matter to someone using RU58841 for hair loss. Nobody applying this to their scalp daily is worried about their steroid profile triggering a doping investigation. The specific feedback mechanism being assessed here, disruption of endogenous testosterone production detectable through urinary steroid markers, isn't the primary safety concern for someone using RU58841 for hair loss, nor are these markers a general test for the systemic effects an androgen receptor antagonist could potentially produce in other tissues.

It's also, on its own narrow terms, a single-dose result. RU58841 is used daily, indefinitely, by the people this article is actually for. A receptor antagonist can occupy androgen receptors throughout the body, in tissue after tissue, without that occupation ever showing up as a detectable shift in this specific urinary marker set, and doing so has nothing to do with whether it's safe. This result doesn't offset the systemic absorption finding above. It just doesn't speak to it.

The researchers are direct about this themselves, and it's the single most relevant sentence in the paper for anyone actually using RU58841: "RU 58841 is generally intended for long-term use in clinical settings. Repeated daily use may result in cumulative or steady-state endocrine adaptations through physiological feedback mechanisms. Therefore, future longitudinal studies are necessary to determine the endocrine effects during chronic daily use."

That's a real gap, not a formality. People using RU58841 for hair loss generally apply it repeatedly, often daily, rather than as a single isolated dose. A single-dose study, however well-conducted, structurally cannot tell you what happens after months or years of daily systemic exposure, particularly when the authors themselves acknowledge that repeated daily exposure may produce cumulative or steady-state endocrine adaptations. The authors also note their own baseline hormone measurements, three samples per participant, may not have captured each person's normal day-to-day variation closely enough to detect a subtle shift even if one existed.

The paper's own conclusion is carefully worded, and worth reading in full rather than summarised: the findings "do not support the hypothesis that RU 58841 acts as a confounding factor of the urinary SP in antidoping analysis," specifically under the single-dose conditions tested. That's a narrower, more precise claim than "RU58841 is hormonally safe," and the difference between those two statements is exactly the distinction worth holding onto.

This study provides direct human evidence against one thing clearly: the specific claim that RU58841 stays local and doesn't reach the bloodstream is no longer defensible. It was directly tested in humans for the first time, and it didn't hold up: RU58841 was detected in every participant. That's the finding that matters here, and it undermines a central premise behind RU58841's appeal: that it's a way to get antiandrogen activity at the scalp while avoiding systemic exposure. It doesn't undermine the underlying pharmacological idea of local receptor antagonism, only the specific claim that this happens without the drug entering circulation.

The absence of a detected hormone-marker shift doesn't soften that. It's a narrow, single-dose result on a mechanism that isn't the primary safety concern for someone applying RU58841 for hair loss, not evidence that chronic systemic exposure to an androgen receptor blocker is fine. What the evidence from RU58841's own drug class does suggest, covered above, is that this mechanism, systemic androgen receptor blockade, carries a documented, quantified pattern of neuropsychiatric and cardiovascular effects in its closest approved relatives. That's a substantive reason for caution grounded in real trial data, not just an absence of data.

What still doesn't exist is any human safety data on the way RU58841 is actually used: daily, unsupervised, for months or years, at doses and concentrations that vary between unregulated online suppliers, one of which, in this very study, sold a product at 60% of its labelled strength. RU58841 remains an unapproved compound with a genuine, newly confirmed systemic exposure profile, a mechanism class with a documented history of significant systemic side effects, and no chronic-use human safety data behind it. We're not covering dosing or sourcing here, in line with our usual approach to unapproved compounds, and this study is a good illustration of why: the honest answer to "is this safe long-term" isn't just that nobody has checked. The available evidence provides more reason for caution than reassurance.

This article is provided for educational purposes and does not constitute medical advice. RU58841 is an unapproved compound not evaluated for safety or efficacy by any regulator; we do not cover dosing, sourcing, or use here. AmpleLab products are cosmetic formulations, unrelated to RU58841, and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.